manganese(III)meso-tetrakis(4-chlorophenyl)porphine-μ-oxodimer
厂家直销
博飞美科提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
PA55751
PERFEMIKER
154089-63-1
C88H48Cl8Mn2N8O
1626.88
*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!
| 产品名称： |
Μ-氧-双四对氯苯基卟啉锰,95% |
| 中文别名： |
双四对氯代苯基卟啉锰;Μ-氧-双四对氯苯基卟啉锰;mu-氧二[5,10,15,20-四(4-氯苯基)-21H,23H-卟啉-N21,N22,N23,N24]二锰;Μ-氧-双四对氯苯基卟啉锰 别名间-四对氯苯基卟吩-Μ-氧化锰(III)二聚体;Μ-氧-双四对氯苯基卟啉锰 5G |
| 英文名称： |
manganese(III)meso-tetrakis(4-chlorophenyl)porphine-μ-oxodimer |
| 英文别名： |
Manganese (III) meso-tetra(4-chlorophenyl)porphine-μ-oxo dimer;manganese(III)meso-tetrakis(4-chlorophenyl)porphine-μ-oxodimer;manganese(III)meso-tetrakis(4-chlorophenyl)porphine-;I-oxodimer;Manganese(3+);oxygen(2-);5,10,15,20-tetrakis(4-chlorophenyl)porphyrin-22,24-diide |
| 品牌： |
PERFEMIKER |
| CAS号： |
154089-63-1 |
| 分子式： |
C88H48CL8MN2N8O |
| 分子量： |
1626.88 |
| 纯度： |
95% |
| 详细描述： |
博飞美科的Μ-氧-双四对氯苯基卟啉锰,95%为卟啉,产品稳定,定制速度快,极大地方便了广大科研客户的使用需求。产品包装为1g。查询关键词:卟啉，154089-63-1，Μ-氧-双四对氯苯基卟啉锰,95%，manganese(III)meso-tetrakis(4-chlorophenyl)porphine-μ-oxodimer，博飞美科，Perfemiker，上海，厂家直销。 |
C1C2C%3dCC(%3dC(C3C%3dCC(%3dCC%3d3)Cl)C3%3dCC%3dC(C(C4C%3dCC(%3dCC%3d4)Cl)%3dC4C%3dCC(C(C5C%3dCC(%3dCC%3d5)Cl)%3dC5C%3dCC%3d1%5bN-%5d5)%3dN4)%5bN-%5d3)N%3d2.ClC1C%3dCC(%3dCC%3d1)C1C2C%3dCC(%3dC(C3C%3dCC(%3dCC%3d3)Cl)C3%3dCC%3dC(C(C4C%3dCC(%3dCC%3d4)Cl)%3dC4C%3dCC(C(C5C%3dCC(%3dCC%3d5)Cl)%3dC5C%3dCC%3d1%5bN-%5d5)%3dN4)%5bN-%5d3)N%3d2.%5bO-2%5d+%7cc%3a12%2c51%2c72%2c111%2ct%3a34%2c47%2c94%2c107%7c)
沪公网安备31011402010658号 
(Cl)Cl.ClC1C(%5bH%5d)%3dC(%5bH%5d)C(%3dC(%5bH%5d)C%3d1%5bH%5d)C1C2C(%5bH%5d)%3dC(%5bH%5d)C(%3dC(C3C(%5bH%5d)%3dC(%5bH%5d)C(%3dC(%5bH%5d)C%3d3%5bH%5d)Cl)C3%3dC(%5bH%5d)C(%5bH%5d)%3dC(C(C4C(%5bH%5d)%3dC(%5bH%5d)C(%3dC(%5bH%5d)C%3d4%5bH%5d)Cl)%3dC4C(%5bH%5d)%3dC(%5bH%5d)C(C(C5C(%5bH%5d)%3dC(%5bH%5d)C(%3dC(%5bH%5d)C%3d5%5bH%5d)Cl)%3dC5C(%5bH%5d)%3dC(%5bH%5d)C%3d1N5%5bH%5d)%3dN4)N3%5bH%5d)N%3d2+%7cc%3a21%2c78%2ct%3a53%2c72%7c)
%3ac(C3%3dCC%3dC(C)C%3dC3)%3ac3N4%5bNi%5dN5c%3a2C%3dCc5%3ac(C2%3dCC%3dC(C)C%3dC2)%3ac2%3an%3ac(%3ac(C5%3dCC%3dC(C)C%3dC5)%3ac4C%3dC3)C%3dC2)C%3dC1)
%3dCC%3d4)%3dC4C%3dCC(%5bN-%5d14)%3dC(C1C%3dCC(C)%3dCC%3d1)C1C%3dCC(N2%3d1)%3dC(C1C%3dCC(C)%3dCC%3d1)C1%3dCC%3dC(C%3d5C2C%3dCC(C)%3dCC%3d2)%5bN-%5d31)
%3dCC%3d4)%3dC4C%3dCC(%5bN-%5d14)%3dC(C1C%3dCC(Cl)%3dCC%3d1)C1C%3dCC(N2%3d1)%3dC(C1C%3dCC(Cl)%3dCC%3d1)C1%3dCC%3dC(C%3d5C2C%3dCC(Cl)%3dCC%3d2)%5bN-%5d31)